Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial

PURPOSE: To evaluate the 1-year efficacy, durability, and safety of faricimab versus aflibercept in patients with neovascular age-related macular degeneration (nAMD) enrolled in the Japan subgroup of the TENAYA trial. STUDY DESIGN: TENAYA (NCT03823287) was a global, phase 3, multicenter, randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Ryusaburo, Honda, Shigeru, Gomi, Fumi, Tsujikawa, Akitaka, Koizumi, Hideki, Ochi, Haruka, Ohsawa, Shino, Okada, Annabelle Ayame
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098238/
https://www.ncbi.nlm.nih.gov/pubmed/37039948
http://dx.doi.org/10.1007/s10384-023-00985-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098238/
https://www.ncbi.nlm.nih.gov/pubmed/37039948
http://dx.doi.org/10.1007/s10384-023-00985-w

Ejemplares similares